Amarakoon S, et al. - Researchers gauged whether or not on-demand bevacizumab treatment every 8 weeks is non-inferior to on-demand bevacizumab every 4 weeks in treating neovascular age-related macular degeneration (nARMD). They randomly assigned a total of 120 nARMD patients to an on-demand regimen of intravitreal bevacizumab (IVB) every 4 or 8 weeks. Findings suggested inferiority of bevacizumab administration on-demand every 8 weeks to administration every 4 weeks at 1 year. Bevacizumab was seen to act longer than 4 weeks in ARMD, thereby, reducing the burden of injections for patients. Both groups demonstrated a reduction in the central retinal thickness.